Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioInvent International AB ( (SE:BINV) ) has shared an update.
BioInvent International AB and Transgene have announced the presentation of translational data and updated clinical results for their oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The Phase 1 study results indicate that BT-001, in combination with pembrolizumab, shows promise as a treatment for advanced refractory tumors, demonstrating tumor shrinkage in both injected and non-injected lesions. This development could enhance the response to immune checkpoint inhibitors in refractory patients, potentially impacting the company’s position in the cancer immunotherapy market.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a biotechnology company focused on the discovery and development of novel immune-modulatory antibodies for cancer immunotherapy. The company collaborates with Transgene, which designs and develops virus-based immunotherapies for cancer treatment.
YTD Price Performance: -28.83%
Average Trading Volume: 84,131
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.8B
Learn more about BINV stock on TipRanks’ Stock Analysis page.